Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of DDGP regiment (gemcitabine,pegaspargase,cisplatin,dexamethasone) for patients with stage Ⅲ/Ⅳ Natural Killer (NK)/T Cell Lymphoma.


Clinical Trial Description

Patients with NK/T cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional chemotherapy of CHOP. The investigators have been proceeding this trial to evaluate the efficacy and safety of the combination chemotherapy regiment DDGP (gemcitabine,pegaspargase, cisplatin, dexamethasone) in the patients with stage Ⅲ/Ⅳ NK/T cell lymphoma. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01501149
Study type Interventional
Source Zhengzhou University
Contact Mingzhi Zhang, Pro,Dr
Phone 13838565629
Email mingzhi_zhang@126.com
Status Recruiting
Phase Phase 4
Start date January 2011
Completion date May 2019

See also
  Status Clinical Trial Phase
Recruiting NCT01501136 - Treatment of Natural Killer/T Cell Lymphoma-I/II Phase 4